Associate Scientist III, Metabolic Diseases
Insitro
Summary
Engineer complex 3D cell models (spheroids and co-cultures) using various cell types for mechanistic studies; develop and qualify workflows to validate drug targets, define mechanism of action and conduct pharmacology studies for drug discovery using techniques such as CRISPR, siRNA and RNAseq.
Job description
Independently develop and optimize in vitro assays by leveraging molecular biology techniques, advanced microscopy and automated instrumentation for metabolic disease phenotyping.
Generate datasets from ex vivo samples for key efficacy and target engagement readouts to enable critical go/no-go decisions; analyze high-throughput datasets using sophisticated Machine Learning-based pipelines.
Lead small projects end-to-end and coordinate handoffs between multi-disciplinary teams to meet key project milestones; generate presentations and publication material for effective scientific communication at the company level.
Adhere to good lab practices and document all experimental parameters meticulously in an Electronic Lab Notebook (ELN) for data integrity.
Requirements
- Master's degree in Biotechnology, Bioengineering or a related field plus two (2) years of experience in a related occupation, OR Bachelor's degree in Biotechnology, Bioengineering or a related field plus five (5) years of progressive experience in a related occupation
- Two (2) years of experience handling primary, immortalized, and iPSC-derived cell lines (such as hepatocytes, fibroblasts and endothelial cells) and engineering complex disease models including co-cultures and spheroids
- Two (2) years of experience executing high throughput screening such as pooled optical, arrayed CRISPR screens and siRNA drug discovery screens
- Two (2) years of experience handling tool compounds such as oligonucleotides, small molecules and antibodies for functional validation, disease phenotyping, and mechanistic studies
- Two (2) years of experience applying molecular biology techniques for gene expression such as qPCR and RNAseq, and protein expression such as Jess, MSD, and Luminex
- Two (2) years of experience developing pharmacology and drug discovery assays, and establishing qualification metrics (Z', % CV, IC50 and reproducibility)
- Two (2) years of experience leveraging advanced microscopy, high-content imaging, and analysis using Machine Learning-based image segmentation pipelines
- Two (2) years of experience with large-scale processing of ex-vivo tissues (liver, fat or pancreas) for downstream assays
- Two (2) years of experience handling state of the art automation instrumentation such as Agilent Bravo, Hamilton STAR, ECHO and Multidrop combi
- Two (2) years of experience with using LIMS and other lab oriented software such as GraphPad Prism (data analysis) and Benchling (Electronic Lab Notebook)
Company overview
Insitro is a pioneering AI therapeutics company founded in 2018 and headquartered in South San Francisco, California. The company leverages machine learning, high-throughput biology, and human genetics to transform traditional drug discovery and development processes. Insitro's innovative approach integrates cutting-edge bioengineering technologies to generate large-scale, high-quality datasets specifically designed to drive machine learning methods. The company focuses on building predictive in vitro human cell-derived disease models that can accurately forecast clinical outcomes, addressing key bottlenecks in pharmaceutical R&D. With a team of 201-500 employees spanning life sciences, machine learning, human genetics, engineering, and drug discovery, Insitro has raised significant funding, including a $400 million Series C round in 2021. The company collaborates with major pharmaceutical partners like Bristol Myers Squibb and Eli Lilly to advance therapeutic programs in areas such as ALS and metabolic diseases, aiming to deliver more effective medicines faster and at lower costs to patients.